Inovio Pharmaceuticals, Inc. (INO) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen.
Analysis Summary
Inovio Pharmaceuticals, Inc. reported revenue of $65343 in the most recent fiscal year, growing at a 5-year CAGR of -61.2%.
Trailing-twelve-month margins: gross margin 100.0%, operating margin -1328.7%, net margin -1300.0%.
At the current price of $1.15, INO has negative trailing earnings (P/E not meaningful) and an ROE of -352.53%. Market capitalisation stands at $79M.
Balance sheet quality for INO: current ratio of 1.4, net cash position of $49.1M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $1.15 |
| Market Cap | $79M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.72 |
| EV / EBITDA | -0.57 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -352.53% |
| Return on Invested Capital | -259.45% |
| Return on Assets | -114.31% |
| Gross Margin | 100.00% |
| Operating Margin | -132871.32% |
| Net Margin | -130000.00% |
Financial Health
| Debt / Equity | 0.39 |
| Current Ratio | 1.40 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -36.80 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| INO | Inovio Pharmaceuticals, Inc. | $79M | 2.72 | -352.5% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price Performance
| 1 month | -4.17% |
| 3 months | +2.68% |
| Year-to-date | -33.91% |
| 1 year | -47.25% |
| 3 years | -76.04% |
| 5 years | -98.82% |
52-Week Range
| 52-week High | $2.72 |
| 52-week Low | $0.56 |
| Avg Volume (90d) | 3.5M |
Dividend History
| Date | Amount | Yield |
|---|---|---|
| 2017-09-28 | $0.0057 | 1.98% |
| 2017-08-29 | $0.0057 | 1.98% |
| 2017-07-27 | $0.0057 | 1.98% |
| 2017-06-28 | $0.0057 | 1.98% |
Related companies: ABOS · ACTU · AGEN · ALEC · FATE · IRD · MCRB
Explore sector: Healthcare · Biotechnology
More sections of INO: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks